Sanofi & GSK Win COVID-19 Vaccine Approval In EU Using Immunobridging Trials

New Biosimilar And Generic Drugs Also Get EMA Nod

The European Medicines Agency said it was possible to use immunobridging studies to authorize COVID-19 vaccines now that a number of COVID-19 vaccines authorized in the EU are proven to be safe and effective and can be used as comparators in trials.

Covid vaccine vials
The seventh COVID-19 vaccine has now been approved in the EU • Source: Shutterstock

VidPrevtyn Beta, from Sanofi and GSK, has become the first COVID-19 vaccine to win EU marketing approval based on immunobridging trials.

Well-justified and appropriately designed immunobridging studies that compare an investigational vaccine with an approved one “are adequate for authorizing future COVID-19 vaccines at this point in the pandemic,” said the European Medicines Agency, whose recommendation

More from Europe

More from Geography

EU Shaping Biotech Act To Unleash SME Potential

 

European companies, in particular small and midsize enterprises, spin-offs and start-ups have a hard time expanding within the single market “because of a complex regulatory framework that is perceived as slow and burdensome,” according to the European Commission.

New EU Filings

 

Brensocatib, Insmed's investigational treatment for non-cystic fibrosis bronchiectasis, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.

‘Tectonic’ Arkansas PBM Legislation May Upend Industry

 
• By 

Industry will fight hard to prevent other states or the federal government from adopting measures similar to Arkansas' law preventing PBMs from owning pharmacies.